ChAdOx1 nCoV-19疫苗接种与出血事件的关联:大型人群队列研究
该研究基于超过8万人的大型人群队列,通过电子问卷比较接种腺病毒载体疫苗与mRNA疫苗后自报皮肤、鼻和牙龈出血的患病率。结果显示,接种单剂腺病毒载体疫苗者皮肤出血的OR为16.0(95%CI 7.5-34.1),鼻出血OR为8.0(4.0-15.8),牙龈出血OR为9.3(4.3-20.0),提示腺病毒载体疫苗可能导致较大比例接种者出现轻度出血事件。
要点
- 接种单剂腺病毒载体疫苗者皮肤出血报告率为3.2%,mRNA疫苗者为0.2%。
- 腺病毒载体疫苗与皮肤出血的OR为16.0(95%CI 7.5-34.1)。
- 鼻出血和牙龈出血的OR分别为8.0和9.3,均显著升高。
核心结论
- 腺病毒载体疫苗可能导致较大比例接种者出现轻度出血事件,而非仅罕见血栓形成伴血小板减少症病例。
研究设计与样本
- 基于正在进行的大型人群队列研究,于2021年第11-13周通过电子问卷询问超过80000名队列参与者新冠疫苗接种及潜在副作用,应答率58%(81267/138924)。
主要发现
- 接种单剂mRNA疫苗的3416人中4人(0.2%)报告皮肤出血副作用,而接种单剂腺病毒载体疫苗的5132人中163人(3.2%)报告,OR=16.0(95%CI 7.5-34.1)。
- 鼻出血的OR为8.0(95%CI 4.0-15.8),牙龈出血的OR为9.3(95%CI 4.3-20.0)。
- 接种者中83%为女性,85%为医护人员,80%年龄在40-55岁。
临床怎么用
- 监测接种腺病毒载体疫苗后轻度出血事件,并进一步研究其机制及与严重血栓栓塞性出血并发症的相似性。
局限性
- 研究基于自报问卷,可能存在报告偏倚;需进一步研究确认机制及与严重血栓并发症的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare prevalence of skin, nose and gingival bleedings after receipt of adeno-vectored or mRNA-vaccines against COVID-19. The hypothesis is that milder symptoms indicating altered thrombocyte function may affect a larger proportion of vaccinated individuals than the recently reported severe cases with thrombosis and thrombocytopenia. METHODS: Using an ongoing large, population-based cohort study, more than 80000 cohort participants were asked through electronic questionnaires about COVID-19 vaccination and potential side effects during weeks 11-13, 2021. The response rate was 58% (81267/138924). Among the vaccinated, 83% were female, 85% health care workers and 80% were aged 40-55 years. The prevalence of self-reported episodes of skin, nose and gingival bleedings were compared after mRNA and adenovirus-vectored vaccination. Estimates were adjusted for age, sex, occupation, previous COVID-19 infection and chronic disease. RESULTS: Four of the 3416 subjects (0.2%) who were vaccinated with a single dose of mRNA vaccine reported skin bleeding as a side effect, as opposed to 163 of 5132 subjects (3.2%) vaccinated with a single dose of the adenovirus-vectored vaccine, OR (odds ratio) = 16.0 (95% confidence interval (CI) 7.5-34.1). Corresponding ORs for nose and gingival bleeding were 8.0 (4.0-15.8) and 9.3 (4.3-20.0), respectively. CONCLUSIONS: These findings could potentially indicate that the adenovirus-vectored vaccine may lead to mild bleeding episodes in a larger proportion of vaccinated individuals, and not only in rare cases with documented thrombosis and thrombocytopenia. Studies are needed to understand the possible mechanisms behind these observations, and to establish or refute whether they share similarities with the severe thromboembolic bleeding complications.
引用
- Trogstad L, Robertson AH, Mjaaland S, et al. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: Large population-based cohort study. Vaccine. 2021. PMID: 34479760. doi:10.1016/j.vaccine.2021.08.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。